Search in:

Advanced search

Expert Opinion on Pharmacotherapy Volume 10, 2009 - Issue 12

Submit an article Journal homepage

144

Views

CrossRef citations to date

Altmetric

Reviews

Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection

Angelo Iacobellis ‘Casa Sollievo Sofferenza’ Hospital, Division of Gastroenterology, IRCCS, viale Cappuccini 1, 71013 San Giovanni Rotondo, Italy +39 08 8241 0263; +39 08 8283 5411; [email protected]

, MD &

Angelo Andriulli ‘Casa Sollievo Sofferenza’ Hospital, Division of Gastroenterology, IRCCS, viale Cappuccini 1, 71013 San Giovanni Rotondo, Italy +39 08 8241 0263; +39 08 8283 5411; [email protected]

Pages 1929-1938 | Published online: 30 Jun 2009

Cite this article
https://doi.org/10.1517/14656560903066811

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Omata M, Shiratori Y. Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C. J Gastroenterol Hepatol 2000;15(Suppl):E134-40
Google Scholar
Shiratori Y, Shiratori Y, Imazeki F, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-24
PubMed Web of Science ®Google Scholar
Poynard T, Poynard T, McHutchison J, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13
PubMed Web of Science ®Google Scholar
Pol S, Carnot F, Nalpas B, et al. Reversibility of hepatitis C virus-related cirrhosis. Hum Pathol 2004;35:107-12
PubMed Web of Science ®Google Scholar
Serpaggi J, Carnot F, Nalpas B, et al. Direct and indirect evidence for the reversibility of cirrhosis. Hum Pathol 2006;37:1519-26
PubMed Web of Science ®Google Scholar
Di Marco V, Almasio PL, Ferraro D, et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007;47:484-91
PubMed Web of Science ®Google Scholar
Everson GT, Balart L, Lee SS, et al. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis. Aliment Pharmacol Ther 2008;27:542-51
PubMedGoogle Scholar
Zois CD, Baltayiannis GH, Karayiannis P, Tsianos EV. Systematic review: hepatic fibrosis-regression with therapy. Aliment Pharmacol Ther 2008;28:1175-87
PubMedGoogle Scholar
Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008;149:399-403
PubMed Web of Science ®Google Scholar
Bruno S, Stroffolini T, Colombo M, et al.; Italian Association of the Study of the Liver Disease (AISF). Sustained virological response to interferon-alfa is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007;45:579-87
PubMed Web of Science ®Google Scholar
Braks RE, Ganne-Carrie N, Fontaine H, et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol 2007;13:5648-53
PubMed Web of Science ®Google Scholar
Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002;35:680-7
PubMed Web of Science ®Google Scholar
Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000;32:673-84
PubMed Web of Science ®Google Scholar
Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-80
PubMed Web of Science ®Google Scholar
Abergel A, Hezode C, Leroy V, et al.; French multicenter study group. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial compared two doses of peginterferon alpha-2b. J Viral Hepat 2006;13:811-20
PubMed Web of Science ®Google Scholar
Helbling B, Jochum W, Stamenic I, et al.; Swiss Association for the Study of the Liver (SASL). HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon a-2a and ribavirin. J Viral Hepat 2006;13:762-9
PubMedGoogle Scholar
Syed E, Rahbin N, Weiland O, et al. Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis. Scand J Gastroenterol 2008;43:1378-86
PubMed Web of Science ®Google Scholar
Roffi L, Colloredo G, Pioltelli P, et al.; Gruppo Epatologico Lombardo. Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis. Antivir Ther 2008;13:663-73
PubMed Web of Science ®Google Scholar
Marrache Y, Consigny MP, Ripault D, et al. Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis. J Viral Hepat 2005;12:421-8
PubMedGoogle Scholar
Floreani A, Baldo V, Rizzotto ER, et al. Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis. J Clin Gastroenterol 2008;42:734-7
PubMedGoogle Scholar
Crippin JS, McCashland T, Terrault N, et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002;8:350-5
PubMed Web of Science ®Google Scholar
Thomas RM, Brems JJ, Guzman-Hartman G, et al. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003;9:905-15
PubMed Web of Science ®Google Scholar
Forns X, García-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003;39:389-96
PubMed Web of Science ®Google Scholar
Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005;42:255-62
PubMed Web of Science ®Google Scholar
Iacobellis A, Siciliano M, Perri F, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007;46:206-12
PubMed Web of Science ®Google Scholar
Tekin F, Gunsar F, Karasu Z, et al. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics. Aliment Pharmacol Ther 2008;27:1081-5
PubMedGoogle Scholar
Annicchiarico BE, Siciliano M, Avolio AW, et al. Treatment of chronic hepatitis C virus infection with pegylated interferon and ribavirin in cirrhotic patients awaiting liver transplantation. Transplant Proc 2008;40:1918-20
PubMedGoogle Scholar
Iacobellis A, Siciliano M, Annicchiarico BE, et al. Sustained virologic responses following standard antiviral therapy in decompensated HCV-infected cirrhotic patients. Aliment Pharmacol Ther 2009 [Epub 17 Apr 2009]
PubMedGoogle Scholar
McHutchinson JG, Manns MP, Longo DL. Definition and management of anaemia in patients infected with hepatitis C virus. Liver Int 2006;26:389-98
PubMedGoogle Scholar
Sulkowski MS, Wasserman R, Brooks L, et al. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004;11:243-50
PubMed Web of Science ®Google Scholar
De Franceschi L, Fattovich G, Turrini F. Haemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000;31:997-1004
PubMed Web of Science ®Google Scholar
Dar Santos AE, Partovi N, Ford JA, Yoshida EM. Use of hematopoietic growth factors as adjuvant therapy for anemia and neutropenia in the treatment of hepatitis C. Ann Pharmacother 2007;41:268-75
PubMed Web of Science ®Google Scholar
Ong JP, Younossi ZM. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleve Clin J Med 2004;71:S17-21
PubMed Web of Science ®Google Scholar
Sulkowski MS. Anemia in the treatment of hepatitis C virus infection. Clin Infect Dis 2003;37(Suppl 4):315-22
PubMed Web of Science ®Google Scholar
Wasserman R, Brau N, Hassanein T, et al. Once weekly epoietin alfa increases hemoglobin and decreases RBV discontinuation among HCV patients who develop anemia on RBV/IFN therapy. Hepatology 2000;32(Suppl):368A
Web of Science ®Google Scholar
Younossi ZM, Ong JP, Collantes R, et al. Darbepoetin alfa for ribavirin-induced anemia in patients with chronic hepatitis C treated with pegylated interferon and ribavirin. Gastroenterology 2004;126(Suppl 2):83B
Google Scholar
Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82
PubMed Web of Science ®Google Scholar
Koirala J, Gandotra SD, Rao S, et al. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy. J Viral Hepatol 2007;14:782-7
PubMed Web of Science ®Google Scholar
Antonini MG, Babudieri S, Maida I, et al. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. Infection 2008;36:250-5
PubMed Web of Science ®Google Scholar
Cooper CL, Al-Bedwawi S, Lee C, Garber G. Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia. Clin Infect Dis 2006;42:1674-8
PubMed Web of Science ®Google Scholar
Forns X, Afdhal NH, McHutchison JG. Review article: pharmacological approaches for the treatment of thrombocytopenia in patients with chronic liver disease and hepatitis C infection. Aliment Pharmacol Ther 2007;26(Suppl 1):29-39
PubMedGoogle Scholar
Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol 2000;95:2936-9
PubMed Web of Science ®Google Scholar
Giannini EG. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther 2003;23:1055-65
Google Scholar
McCormick PA, Murphy KM. Splenomegaly, hypersplenism and coagulation abnormalities in liver disease. Baillieres Best Pract Res Clin Gastroenterol 2000;14:1009-31
PubMedGoogle Scholar
Weksler BB. Review article: the pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease. Aliment Pharmacol Ther 2007;26(Suppl 1):13-9
PubMed Web of Science ®Google Scholar
Adinolfi LE, Giordano MG, Andreana A, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol 2001;113:590-5
PubMed Web of Science ®Google Scholar
Rios R, Sangros E, Herrero I, et al. The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Am J Gastroenterol 2005;100:1311-16
PubMed Web of Science ®Google Scholar
Bordin G, Ballaré M, Zigrossi P, et al. A laboratory and thrombokinetic study of HCV-associated thrombocytopenia: a direct role of HCV in bone marrow exhaustion? Clin Exp Rheumatol 1995;13(Suppl 13):39-43
PubMed Web of Science ®Google Scholar
Wang R, Furihata K, McFarland JG, et al. An amino acid polymorphism within the RGD binding domain of platelet membrane glycoprotein IIIa is responsible for the formation of the Pena/Penb alloantigen system. J Clin Invest 1992;90:2038-43
PubMedGoogle Scholar
Nagamine T, Ohtuka T, Takehara K, et al. Thrombocytopenia associated with hepatitis C viral infection. J Hepatol 1996;24:135-40
PubMed Web of Science ®Google Scholar
Bauduer F, Marty F, Larrouy M, Ducout L. Immunologic thrombocytopenic purpura as presenting symptom of hepatitis C infection. Am J Hematol 1998;57:338-40
PubMed Web of Science ®Google Scholar
McHutchison JG, Geoffrey Dusheiko, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007;357:2227-36
PubMed Web of Science ®Google Scholar
Colombo M, Kuo G, Choo QL, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989;2:1006-8
PubMed Web of Science ®Google Scholar
Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000;32:852-8
PubMed Web of Science ®Google Scholar
Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-96
PubMed Web of Science ®Google Scholar
Wiesner RH, Sorrell M, Villamil F. The international liver transplantation society expert. Report of the first international liver transplantation society expert panel consensus Conference on liver transplantation and hepatitis C. Liver Transpl 2003;9:S1-9
PubMed Web of Science ®Google Scholar
Fink S, Gaglio PJ. Hepatitis C in liver transplant patients. Curr Hepat Rep 2008;7:81-7
Google Scholar
Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatits C. Ann Intern Med 2008;149:399-403
PubMed Web of Science ®Google Scholar
Saracco G, Rosina F, Abate ML, et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alfa 2b. Hepatology 1993;18:1300-5
PubMedGoogle Scholar
Shiffmann M, Hofmann CM, Thompson EB, et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology 1997;26:780-5
PubMedGoogle Scholar
Ziol M, Van Nhieu JT, Roudot-Thoraval F, et al. A histopathological study of the effects of 6-month versus 12-month interferon alpha-2b therapy in chronic hepatitis C. J Hepatol 1996;25:833-41
PubMedGoogle Scholar
Bonis PA, Ioannidis JP, Cappelleri JC, et al. Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: a meta-analysis of diagnostic test characteristics. Hepatology 1997;26:1035-44
PubMed Web of Science ®Google Scholar
Aghemo A, Rumi MG, Soffredini R, et al. Impaired response to interferon-α2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection. Antivir Ther 2006;11:797-802
PubMedGoogle Scholar
Carrión JA, Martínez-Bauer E, Crespo G, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009;50:719-28
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date